向PYK2,因特雷克提尼布通过调节TGFβ2信号通路来缓解小鼠前子白内障
Xuefei Ding1,2, Xiaohe Li3, Rui Fang1,2
1Beijing Tongren Hospital, Beijing, 100730, China.
Molecular medicine (Cambridge, Mass.)
|September 28, 2024
概括
恩特雷克提尼布通过抑制细胞迁移和增殖,有效治疗纤维性白内障. 这种药物向PYK2蛋白,阻断关键信号通路,以缓解白内障手术后的纤维化.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 纤维性白内障是白内障提取后的一个常见并发症.
- 目前的治疗方法缺乏有效性,需要新的治疗策略.
- 这项研究探讨了Entrectinib对抗纤维性白内障的潜力.
研究的目的:
- 为了研究Entrectinib对纤维性白内障的治疗作用.
- 阐明Entrectinib作用的潜在分子机制.
- 为了评估Entrectinib在体外和体外模型中的有效性.
主要方法:
- 使用了人类透镜细胞 (SRA 01/04) 和C57BL/6J小鼠模型.
- 通过裂纹灯和H&E染色来评估白内障的严重程度.
- 量化纤维化标志物 (α-SMA,FN,Col I) 和细胞行为 (增殖,迁移).
- 采用分子对接和生物物理测试来确定Entrectinib的分子标.
主要成果:
- 在这两种实验模型中,恩特雷克提尼布显著改善了纤维性白内障.
- 下调的纤维化标志物 (α-SMA,Col I,FN) 和上调的E-cadherin.
- 抑制了透镜细胞的增殖和迁移.
- 确定PYK2为目标,阻断TGFβ2/Smad和TGFβ2/非Smad通路.
结论:
- 恩特雷克提尼布向PYK2,抑制EMT和相关的信号通路.
- 这种机制有效地缓解纤维性白内障.
- 恩特雷克提尼布作为纤维性白内障的潜在临床治疗方法具有前景.
相关概念视频
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Receptor Tyrosine Kinases
12.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.4K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Enzyme-linked Receptors
77.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.5K


